DIRS.INFO The most relevant business & tech news

☆ Wells Fargo becomes bullish on this biotech company
▼ + stars: | 2024-04-24 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.5 billion in peak sales, topping his prior $1.1 billion estimate. "We think [the] Crinecerfont [opportunity] is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opportunity. The NBI-'845 treatment could be "another blockbuster opportunity," Bansal said, citing the treatment's once-daily administration as a factor in his assessment.

Persons: Mohit, Bansal, Takeda, — CNBC's Michael Bloom Organizations: Biosciences Locations: Wells Fargo

☆ Art Basel Hong Kong: Collectors return to Asia’s biggest art fair despite cooling market
▼ + stars: | 2024-03-29 | by ( Stephy Chung | ) edition.cnn.com time to read: +9 min

Hong Kong CNN —Picture Vladimir Putin, Angela Merkel and George W. Bush as 7-year-olds. Noemi Cassanelli/CNNAsia’s largest art fair, which concludes Saturday, has returned to “pre-pandemic scale,” as organizers put it. Hong Kong artist Mak2's installation in the fair's "Encounters" section. A colorful booth by Dvir Gallery, based in Paris, Tel Aviv and Brussels, which participated in the Hong Kong fair for the first time. So while Art Basel is a “very international platform,” Chan said, it still provides the chance to showcase homegrown talent.

Persons: Vladimir Putin, Angela Merkel, George W, Bush, Lí, Noemi Cassanelli, Hong, Hong Kong’s, ”, William Leung, fairgoer, “, Ivy Haldeman, François Ghebaly, It’s, it’s, “ It’s, Victoria Miro, Wirth, Mark Bradford, Philip Guston, Ed Clark, ” Keith Tsuji, Willem de Kooning’s, Kooning, Fuyuhiko Takata, Yoko Ono’s, Takata, Fuyuhiko, Louise Delmotte, I’m, ” Takata, fairgoers, Jaume Plensa, Mary Sabbatino, Sabbatino, Mak2, Teppei, Maho Kubota, Alexie, Kantor, Trevor Yeung, Stephen Wong, people’s, Hilda Chan, London’s, ” Chan Organizations: Hong Kong CNN, Art Basel, CNN, “, Hauser, Hauser & Wirth, Galerie Lelong, The, Hong, Dvir, Hong Kong, CNN Hong, London’s Tate Locations: Hong Kong, Beijing, Hong Kong ., China, New York, Art Basel Hong Kong, Los Angeles, Asia, American, Spanish, York, Paris, Australian, Paris , Tel Aviv, Brussels, Hong

☆ Dengue Spreads Fast in Brazil Prompting Emergency Health Measures
▼ + stars: | 2024-02-07 | by ( Feb. | At P.M. | ) www.usnews.com time to read: +3 min

By Ricardo Brito and Anthony BoadleBRASILIA (Reuters) - Dengue fever has surged in Brazil's hot rainy season, forcing health authorities to take emergency measures and start mass vaccination against the mosquito-borne illness. In the first five weeks of this year 364,855 cases of infection have been reported, the Health Ministry said, four times more than dengue cases in the same period of 2023. The rapid spread of dengue has caused 40 confirmed deaths, the ministry said, and a further 265 are being investigated. The Health Ministry has set up an emergency center to coordinate operations against dengue across Brazil. Dengue fever symptoms include a high fever, headache, vomiting, muscle and joint pains, and an itching skin rash.

Persons: Ricardo Brito, Anthony Boadle BRASILIA, Qdenga, Tedros Adhanom, Anthony Boadle, Angus MacSwan Organizations: Reuters, Health Ministry, Federal, Army, Brazilian Air Force, World Health Organization, WHO, El Locations: Brazil, Minas Gerais, Brasilia, Brasilia ., Rio de Janeiro, Europe, America

☆ 2023 was a tough year for us, but we expect a rebound in 2024: Takeda Pharmaceuticals CEO
▼ + stars: | 2024-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email2023 was a tough year for us, but we expect a rebound in 2024: Takeda Pharmaceuticals CEOChristophe Weber, CEO of Takeda Pharmaceuticals says product pipeline was very positive in the last quarter and shares his business outlook for 2024.

Persons: Christophe Weber, Takeda Organizations: Takeda, Takeda Pharmaceuticals

☆ Pharma giants are hiking prices on over 500 drugs for 2024, report says
▼ + stars: | 2024-01-02 | by ( Rebecca Rommen | ) www.businessinsider.com time to read: +1 min

Read previewPharmaceutical giants Pfizer, Sanofi, and Takeda Pharmaceutical are due to raise prices on more than 500 drugs in the US from January, according to the Reuters news agency. This story is available exclusively to Business Insider subscribers. It comes as the pharmaceutical sector prepares for the Biden Administration's release of discounted prices for 10 high-cost drugs in September. AdvertisementFurther in the future, the Biden administration's Inflation Reduction Act includes new provisions to allow the government's Medicaid health program to directly negotiate drug prices with their makers — but only from 2026. It said that three companies, including GlaxoSmithKline, are poised to lower prices in January across at least 15 drugs.

Persons: —, Takeda, Biden Organizations: Service, Pfizer, Sanofi, Takeda Pharmaceutical, Reuters, Business, Biden, GlaxoSmithKline

TOKYO (AP) — The bid-rigging trial around the Tokyo Olympics played out Tuesday in a Japanese courtroom — more than two years after the Games closed — with advertising giant Dentsu and five other companies facing criminal charges. Executives or management-level officials at each of the accused companies, and Tokyo Olympic organizing committee official Yasuo Mori, have been charged with violating anti-monopoly laws. Speaking in Tokyo district court, he said no bid process was ever decided upon or set up by the Tokyo Olympic organizing committee. Once the Olympics landed in Tokyo, Dentsu became the chief marketing arm of the Games and raised a record $3.3 billion in local sponsorship. Takahashi was a member of the Tokyo Olympic organizing committee and wielded powerful influence over the Olympic business.

Persons: Koji Henmi, Yasuo Mori, Cerespo, Dentsu, Sebastian Coe, Thomas Bach, Genta Yoshino, Henmi, ” Yoshino, Yoshino, Yoshiro Mori, Toshiro Muto, Tsunekazu Takeda, Haruyuki Takahashi, Takahashi Organizations: TOKYO, Tokyo Olympics, Tokyo Olympic, Tokyu Agency, Olympic Committee, IOC, Bank of Japan, Tokyo, Japanese Olympic Committee, Tokyo Metropolitan Government, Olympic, Aoki Holdings, Paris Locations: Tokyo, Dentsu, Switzerland, Japan, Sapporo, French, Salt Lake City, Osaka, paris

"Given the fast-changing landscape, I believe those who move fast (with wage hikes) should become competitive." A demand made this year by Rengo, Japan's largest trade union confederation, for pay hikes of "around 5%" resulted in average wage hikes of 3.58% among major companies. Six out of 10 economists in a Reuters poll expect major firms' pay hikes in 2024 to exceed this year's. The key, however, would be whether wage hikes broaden to smaller firms and those in the regional areas. A report by the BOJ's regional branch managers in October warned wage hikes remained uneven among sectors with many firms undecided on next year's pay increments.

Persons: Kim Kyung, Takeshi Niinami, Fumio, Kazuo Ueda, Hisashi Yamada, Rengo, Atsushi Takeda, Kishida, Keita Kondo, Tetsushi Kajimoto, Kentaro Sugiyama, Sam Holmes, Leika Organizations: REUTERS, Rights, Suntory Holdings Ltd, Reuters, Meiji, Life Insurance, Suntory Holdings, Bank, Japan, Hosei University, OECD, UA Zensen, Itochu Economic Research Institute, Thomson Locations: Tokyo, Japan, Ukraine, Saitama

☆ Japan's export growth slows as China, global downturn risks loom
▼ + stars: | 2023-11-16 | by ( Tetsushi Kajimoto | ) www.reuters.com time to read: +3 min

A worker is seen among newly manufactured cars awaiting export at port in Yokohama, Japan, November 15, 2017. Weak exports have complicated Japan's efforts to spur economic growth with sluggish domestic demand also weighing on the post-pandemic recovery. Japan's export growth slowsJapan's economy weakened in July-September, snapping two straight quarters of expansion on soft consumption and exports, data showed on Wednesday. By destination, exports to China, Japan's largest trading partner, fell 4.0% year-on-year in October, posting 11 straight months of declines. The trade balance came to a deficit of 662.5 billion yen ($4.38 billion), versus the median estimate for a 735.7 billion yen deficit.

Persons: Toru Hanai, Atsushi Takeda, Tetsushi Kajimoto, Satoshi Sugiyama, Sam Holmes Organizations: REUTERS, TOKYO, Ministry of Finance, Itochu Economic Research Institute, Thomson Locations: Yokohama, Japan, China, United States, Europe

☆ Cancer drug developer Hutchmed aims to be sustainably profitable in 2025: CEO
▼ + stars: | 2023-11-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCancer drug developer Hutchmed aims to be sustainably profitable in 2025: CEOHutchmed's CEO and Chief Strategy Officer Weiguo Su explains the company's profit trajectory after its Takeda-partnered metastatic colorectal cancer drug received FDA approval.

Persons: Weiguo Su, Takeda Organizations: Cancer

[1/2] Mosquitoes are seen on stagnant water on the roadside during countrywide dengue infection, in Dhaka, Bangladesh, August 24, 2023. REUTERS/Mohammad Ponir Hossain/File Photo Acquire Licensing RightsCompanies Takeda Pharmaceutical Co Ltd FollowLONDON, Oct 6 (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Mohammad Ponir Hossain, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: REUTERS, Takeda Pharmaceutical, World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration, Thomson Locations: Dhaka, Bangladesh, United States, Europe, Africa, Asia, Latin America, Vietnam, Saharan Africa, EU

☆ Dengue Will 'Take Off' in Southern Europe, US, Africa This Decade, WHO Scientist Says
▼ + stars: | 2023-10-06 | by ( Oct. | At A.M. | ) www.usnews.com time to read: +4 min

By Jennifer RigbyLONDON (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Earlier this week, the WHO recommended Takeda Pharmaceuticals' Qdenga vaccine for children aged 6 to 16 in areas where the infection is a significant public health problem. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Jennifer Rigby LONDON, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration Locations: United States, Europe, Africa, Asia, Latin America, Bangladesh, Vietnam, Saharan Africa, EU

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

LONDON (AP) — The World Health Organization authorized a second malaria vaccine on Monday, a decision that could offer countries a cheaper and a more readily available option than the world's first shot against the parasitic disease. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Alister Craig, an emeritus professor at the Liverpool School of Tropical Medicine, said he would recommend countries trying to get the GSK vaccine switch to the Oxford vaccine instead. Neither of the malaria vaccines stop transmission so immunization campaigns alone won’t be enough to stop epidemics. In a separate decision, WHO's expert group also authorized the dengue vaccine made by Takeda, which was previously approved by the European Union drug regulator.

Persons: Tedros Adhanom Ghebreyesus, ” Tedros, Tedros, it’s, ”, John Johnson, ” Johnson, Melinda Gates, Alister Craig, Craig, Takeda, Jamey Keaten Organizations: World Health Organization, WHO, Oxford University, Serum Institute of India, Research, Oxford, GSK, Melinda Gates Foundation, Serum, Liverpool School, Tropical, European Union, Associated Press, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Ghana, Burkina Faso, Africa, Oxford, Bangladesh, Geneva

☆ Israeli cyber firm Legit Security raises $40 million in private funding
▼ + stars: | 2023-09-20 | by ( ) www.reuters.com time to read: +1 min

JERUSALEM, Sept 20 (Reuters) - Israeli cybersecurity firm Legit Security said on Wednesday it raised $40 million in a private funding round led by venture capital fund CRV. Since its founding in September 2020, Legit has raised a total of $77 million. It noted that its customer base includes brands such as Google, the NYSE, Kraft Heinz and Takeda Pharmaceuticals. On Tuesday, Israeli cyber firm Cato Networks said it raised $238 million in a late stage funding round, valuing the company at $3 billion. Israel has emerged as a global leader in cyber security in recent years.

Persons: TCV, Kraft Heinz, Takeda, Steven Scheer Organizations: Bessemer Venture Partners, Google, NYSE, Kraft, Takeda Pharmaceuticals, Cato Networks, Thomson Locations: CRV, Israel

☆ Takeda says it has 40 clinical-stage medicines in the pipeline
▼ + stars: | 2023-07-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTakeda says it has 40 clinical-stage medicines in the pipelineChristophe Weber, CEO of Takeda, says there may be some setbacks in research and development, but most of those drugs should fuel the company's growth in the future.

Persons: Takeda, Christophe Weber

☆ Japan's Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine
▼ + stars: | 2023-07-27 | by ( ) www.reuters.com time to read: +2 min

Companies Takeda Pharmaceutical Co Ltd FollowTOKYO, July 27 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) posted first-quarter profit that beat analysts' estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine. Operating profit rose 12% from a year earlier to 168.6 billion yen ($1.2 billion) in the three months through June 30, the drugmaker said. That compared with an average forecast of 150.7 billion yen from six analysts polled by Refinitiv. The company held its forecast for full-year operating profit at 349 billion yen. Analysts expect 481.1 billion yen on average for the year.

Persons: Takeda, Rocky Swift, Tom Hogue, Robert Birsel Organizations: Takeda Pharmaceutical, Refinitiv, Therapeutics, Shire Plc, Nikkei, Thomson Locations: Japan, United States, U.S

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market. Foreign pharmaceuticals firms have struggled to cement any inroads they have made into the world's second-largest economy, with the government maintaining a drug procurement programme that forces them to slash their prices and refusing to approve the use of any foreign COVID-19 vaccines during the pandemic. But as China pursues home-grown modernisation it will also open up "more development opportunities for foreign-funded enterprises, including the pharmaceutical industry," Wang told the meeting. Wang told the meeting on Wednesday that his ministry will expand the channels of communication for responding to and solving concerns, with the meeting resulting in 25 specific suggestions to be taken forward. Reporting by Joe Cash; Additional reporting by Kevin Yao;Editing by Elaine HardcastleOur Standards: The Thomson Reuters Trust Principles.

Persons: Roche, Takeda, Wang Wentao, Wang, Li Qiang, Li, drugmakers, Joe Cash, Kevin Yao, Elaine Hardcastle Organizations: China's Commerce, AstraZeneca, Bayer, Merck, Novo Nordisk, Pfizer, Sanofi, Moderna, Wednesday, Economic, Thomson Locations: BEIJING, China, Tianjin

"The tankan confirmed our view that Japan's economy is on track for a moderate recovery," said Atsushi Takeda, chief economist at Itochu Economic Research Institute. "While input prices have declined, output prices continue to rise in a sign companies are being able to pass on costs. Big manufacturers expect business conditions to improve three months ahead, while non-manufacturers project a deterioration on worries over high costs, the tankan showed. The tankan showed corporate inflation expectations moderate in June from three months ago, but remaining above the BOJ's target five years down the road. Companies expect inflation to hit 2.6% a year from now, down from a 2.8% projection made in March, and 2.2% in three years, also lower than 2.3% in March.

Persons: Atsushi Takeda, Kazuo Ueda, Leika Kihara, Shri Navaratnam Organizations: Big, Bank of Japan's, Itochu Economic Research Institute, Nikkei, Companies, Thomson Locations: TOKYO

☆ Japan business sentiment improves in second quarter, Bank of Japan's tankan survey shows
▼ + stars: | 2023-07-03 | by ( ) www.cnbc.com time to read: +1 min

Tokyo Skytree (R) and Mount Fuji are seen from the I-link Town observatory in Ichikawa city, Chiba prefecture, east of Tokyo on July 2, 2023. Japanese business sentiment improved in the second quarter as raw material costs peaked and the removal of pandemic curbs lifted factory output and consumption, a central bank survey showed, a sign the economy was on course for a steady recovery. Companies expect to increase capital expenditure and project inflation to stay above the Bank of Japan's 2% target five years ahead, the quarterly "tankan" showed, offering policymakers hope that conditions for phasing out their massive monetary stimulus may be gradually falling into place. Strong capital expenditure also led to brighter sentiment among machinery makers," said Atsushi Takeda, chief economist at Itochu Economic Research Institute. "The tankan confirmed our view that Japan's economy is on track for a moderate recovery."

Persons: Atsushi Takeda Organizations: Mount, Bank of Japan's, Itochu Economic Research Institute Locations: Tokyo, Mount Fuji, Ichikawa city, Chiba prefecture

☆ Uniqlo-owner's shares could soar by 50% over 3-5 years: Japan fund manager
▼ + stars: | 2023-06-16 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailUniqlo-owner's shares could soar by 50% over 3-5 years: Japan fund managerMasakazu Takeda, portfolio manager at Hennessy Japan Fund, says shares of Fast Retailing, the company behind Uniqlo, could rise by 50% over the next 3-5 years thanks to the company expansion in Europe and the United States.

Persons: Masakazu Takeda Organizations: Hennessy Japan Fund, Retailing Locations: Japan, Europe, United States

☆ A pledge to fight climate change is sending money to strange places
▼ + stars: | 2023-06-01 | by ( ) www.reuters.com time to read: +10 min

That failure has helped keep climate finance at the top of the agenda at annual U.N. climate conferences, such as last year’s COP27, held in Sharm el-Sheikh, Egypt. Some officials from potential recipient countries say that, before more money starts to flow, clearer definitions of what qualifies as climate finance and more transparency in reporting contributions are needed. A SIMEST official said that the agency’s work is not focused on climate change and that it is not involved in Italy's climate finance reporting. Source: Reuters analysis of climate finance data nations reported to the U.N. Japan’s foreign ministry, not JICA, is responsible for reporting climate finance to the U.N., Takeda said.

Persons: COP27, Matthew Samuda, Venchi, hasn’t, Fred Béliard, Nicolas Fierens Gevaert, Mohammad Hossain, Sachiko Takeda, Takeda, Hiroshi Onuma, Matarbari, “, ” Organizations: Jamaica's Ministry of Economic, Reuters, Italy's Ministry of Environment and Energy Security, United, Marriott, Fatima Group, U.S . State Department, Roja, French Development Agency, U.S, Power Cell, Japan International Cooperation Agency, Japan’s Ministry of Foreign Affairs Locations: Paris, Sharm el, Sheikh, Egypt, Dubai, Jamaica's, Japan, China, Indonesia, Asia, SIMEST, Italy, United States, Haitien, Haiti, Marriott, U.S, Belgium, Argentina, France, Mexico, Kenya, South Africa, Bangladesh, San Francisco, Germany, “ Japan

☆ China's rising clout spotlighted at finance chief meetings before G7 summit
▼ + stars: | 2023-05-15 | by ( Tetsushi Kajimoto | ) www.reuters.com time to read: +4 min

China is among the biggest markets for most G7 countries, particularly for export-reliant economies such as Japan and Germany. In a joint statement on Saturday, the G7 finance chiefs stressed the urgency of addressing debt vulnerabilities in low- and middle-income countries, mentioning Zambia, Ethiopia, Ghana and Sri Lanka. "There were talks about coercion" at the G7 finance leaders' meeting, the Japanese finance ministry official said. The G7 summit will most likely have a special session on China to debate Beijing's "economic coercion" against other countries, according to a Reuters report. "No matter how the G7 want to fence in the Global South, it's not easy," said Atsushi Takeda, chief economist at the Itochu Economic Research Institute.

☆ Seven & I has a 'long runway for growth,' says portfolio manager
▼ + stars: | 2023-04-28 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSeven & I has a 'long runway for growth,' says portfolio managerMasakazu Takeda of Hennessy Japan Fund says there's significant scope for Seven & I to increase its number of stores "organically and inorganically."

☆ See the pitch deck a Wharton grad used to raise $30 million to tackle one of healthcare's most expensive problems
▼ + stars: | 2023-04-26 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +2 min

Digestive health issues are common and costly to treat. The startup said this month that it raised $30 million from investors to scale its platform. Earlier this month, Oshi announced that it raised a $30 million Series B round led by Koch Disruptive Technologies. Oshi Health removed financial details from the pitch deck it used to raise $30 million in Series B before sharing the presentation with Insider. See the presentation Oshi Health used to raise $30 million:

☆ See the 16-slide presentation a startup used to sell CVS and Flare on a new approach to treating digestive issues like IBS
▼ + stars: | 2023-04-19 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +2 min

Digestive health issues are common and costly to treat. The startup said this month that it raised $30 million from investors to scale its platform. That's what Oshi Health, a startup that offers care for digestive issues, wants to change. Oshi Health removed financial details from the pitch deck it used to raise $30 million in Series B before sharing the presentation with Insider. See the presentation Oshi Health used to raise $30 million:

Search resuls for: "Takeda"

25 mentions found